Compositions and methods for treating cancers with atypical BRAF mutations

摘要

The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of cancer in a subject carrying an atypical BRAF mutation (ie, a non-V600E/K BRAF mutation), which is an ERK inhibitor. Are provided, pharmaceutical compositions, and kits. Also provided are methods for identifying a subject with an atypical BRAF variant cancer who is expected to benefit from a treatment that includes an ERK inhibitor. In one aspect, the ERK inhibitor is BVD-523.